Cochlear-Oticon merger partially prohibited

The Competition and Markets Authority has partially prohibited the completed acquisition of Oticon Medical by Cochlear - two of the largest suppliers of hearing implants in the UK.

The CMA's Phase 2 inquiry group, of which DT Economics Managing Partner David Thomas was a member, found that the merger would lead to a substantial lessening of competition in bone conduction solution products - implants that bypass damaged parts of the ear, converting sounds into vibrations sent directly to the inner ear. The decision prevents worse outcomes for patients who rely on these devices and higher prices for the NHS.

Further details on the CMA's case page:

https://www.gov.uk/cma-cases/cochlear-slash-oticon-merger-inquiry